{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-023462","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.322300+00:00","generated_at":"2026-05-15T21:39:30.611070+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Verastem posts updated corporate presentation; no specific financial or clinical data disclosed in filing","bullets":["Corporate presentation dated March 4, 2026, furnished as Exhibit 99.1 to Form 8-K.","Presentation titled 'Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers'.","No revenue, trial results, or other material metrics provided in the 8-K or the exhibit excerpt."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-023462","json":"https://secwatch.observer/filing/0001104659-26-023462.json","markdown":"https://secwatch.observer/filing/0001104659-26-023462.md","text":"https://secwatch.observer/filing/0001104659-26-023462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926023462/0001104659-26-023462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926023462/tm267866d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:39:30.611070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}